What Is Tirzepatide? A Research Overview of the Dual Agonist

June 24, 2026

Tirzepatide is a synthetic dual incretin receptor agonist: a single engineered peptide designed to bind and activate two receptors at once — the GIP and GLP-1 receptors. It is supplied strictly for research use only, and is not for human or veterinary use. This overview explains what the molecule is, how the dual agonist mechanism is understood at a cell-signalling level, and why it has become a focus of preclinical metabolic research.

What tirzepatide is

Tirzepatide is a synthetic peptide belonging to the incretin-mimetic class. In laboratory and supplier catalogues it is frequently searched for simply as "tirz", and it is characterised as a dual agonist — a single engineered peptide designed to engage two distinct receptor targets simultaneously rather than one. Structurally it is a single-chain peptide backbone modified to confer stability and multi-receptor binding, and it is typically handled in the laboratory as a lyophilised (freeze-dried) powder to be reconstituted for in vitro or preclinical work.

The term "incretin" refers to gut-derived hormones that participate in signalling around nutrient intake and energy balance. Tirzepatide's design draws on the sequences and pharmacology of these native signalling molecules, engaging two incretin receptors — the GIP (glucose-dependent insulinotropic polypeptide) receptor and the GLP-1 (glucagon-like peptide-1) receptor — within a single construct. Structural modifications to the peptide backbone are understood to extend its stability and half-life in research contexts, which is one reason it is a convenient reagent for extended in vitro assays. It is this deliberate dual-target profile, combined within one molecule, that distinguishes tirzepatide from single-agonist research peptides.

All material discussed here is intended for research use only. Nothing in this article describes or implies any human or veterinary application.

How it works: the dual agonist mechanism

The defining feature of tirzepatide is agonism at two G-protein-coupled receptors. Each receptor sits within its own signalling context, and the research interest lies in how simultaneous engagement of both is observed to influence cellular responses in model systems.

GIP receptor (glucose-dependent insulinotropic polypeptide): a class B GPCR that, when activated, is classically coupled to Gs proteins and the generation of intracellular cyclic AMP (cAMP). GIP-receptor pharmacology is of interest because the interplay between GIP and GLP-1 signalling within a single construct is not fully resolved, making dual agonists useful tools for dissecting these pathways.
GLP-1 receptor (glucagon-like peptide-1): a related class B GPCR, also coupled to cAMP generation. In model systems, GLP-1 receptor signalling has been studied extensively in the context of insulin-secreting cell lines and nutrient-responsive pathways.

Because both receptors are class B GPCRs that converge, in part, on cAMP-linked cascades, a central research question is how the relative potency (the "balance") across the two targets shapes the net signalling output in a given cell type. A single-agonist peptide engages only one of these pathways; conceptually, a dual agonist such as tirzepatide allows both to be activated by one molecule, which is why it is used as a tool to probe how the two signals combine. Reconstituted tirzepatide is therefore commonly used in receptor-binding, cAMP-accumulation and related in vitro assays where each pathway can be examined independently and in combination.

Why researchers study it

Tirzepatide is of interest in preclinical research primarily as a tool for studying incretin biology and energy-balance signalling. Because it acts on two receptors implicated in metabolic regulation, it offers a single reagent with which to investigate how converging pathways interact — something that is difficult to model with single-target compounds alone.

Areas where the peptide has been studied, or is of research interest, include receptor-signalling characterisation, comparative pharmacology against single- and triple-agonist peptides, and structure-activity investigations of multi-agonist design. These are questions of mechanism and molecular pharmacology, explored in cell-based and preclinical systems. This article makes no therapeutic, clinical or weight-related claims, and none should be inferred: the value of tirzepatide in this context is as a research reagent for understanding biology.

Purity, COA and formats at Reta Research

For laboratory work, the identity and purity of a research peptide are as important as the sequence itself. Tirzepatide at Reta Research is supplied as a lyophilised powder intended for reconstitution in the laboratory, and each batch is accompanied by documentation so that researchers can verify what they are working with.

Our approach to analytical verification is described on the Quality Testing page, which outlines the methods used to assess identity and purity. A corresponding Certificate of Analysis (COA) is made available so that the reported purity and analytical results can be reviewed before material is used in any assay. Reviewing the COA against your own experimental requirements is good practice for reproducible research.

As with everything in our catalogue, tirzepatide is offered for research use only and is not for human or veterinary use.

Frequently asked questions

What does "tirz" stand for?

"Tirz" is simply the common shorthand researchers use for tirzepatide; it is not a separate compound or an abbreviation of distinct words. The peptide referred to as "tirz" is therefore tirzepatide — the synthetic dual GIP/GLP-1 incretin receptor agonist described throughout this article.

Is tirzepatide the same as retatrutide?

No. Tirzepatide is a dual agonist that engages the GIP and GLP-1 receptors, whereas retatrutide is characterised as a triple agonist that additionally engages the glucagon receptor. They are distinct research peptides with different receptor profiles. For a fuller side-by-side discussion see our Retatrutide vs Tirzepatide comparison, or read What Is Retatrutide? for an overview of the triple agonist.

What sizes are available?

Tirzepatide is offered in several vial presentations to suit different research scales. The current formats and their specifications are listed on the Tirzepatide product page, which is kept up to date with available options.

Is it third-party tested?

Analytical verification is central to how the material is supplied. Details of the testing methodology are set out on our Quality Testing page, and a Certificate of Analysis is provided so the reported results can be reviewed prior to use.